Report: Thursday, July 30, 2026, at approximately 7:00 a.m. ET
Conference call: 9:00 a.m. ET
Management: CEO Sal Mancuso and CFO Heather Newman (investor.altria.com)
Altria enters the quarter with strong operating momentum—and a substantially higher valuation—after first-quarter adjusted EPS grew 7.3% and exceeded expectations. The central question is no longer whether the cigarette business can offset declining volumes with price and productivity. It is whether the unusually favorable first-quarter combination of moderating cigarette declines, strong pricing, duty-drawback benefits and share repurchases can persist strongly enough to warrant higher full-year guidance.
The underlying setup is favorable. Q2 2025 was a weak volume comparison, with adjusted domestic cigarette shipments down 10.5%, while the decline moderated to 4% in Q1 2026. If that improvement largely held through Q2, smokeable profit growth should remain healthy. At the same time, investors need evidence that the nationwide launch of on! PLUS is generating genuine consumer demand rather than merely pipeline inventory. (investor.altria.com)
With MO closing at $75.03 on July 29, the shares have risen approximately 30% year to date and 10% since the day before Q1 earnings. At roughly 13.2 times the 2026 consensus EPS estimate and a dividend yield near 5.7%, the stock remains inexpensive in absolute terms, but the earnings bar is much higher than it was three months ago.
| Metric | Q2 2026 consensus | Q2 2025 actual | Implied change |
|---|---|---|---|
| Adjusted EPS | $1.50 | $1.44 | +4.2% |
| Revenue after excise taxes | ~$5.3B | $5.29B | Approximately flat |
| FY 2026 adjusted EPS | $5.70 | $5.42 in 2025 | +5.2% |
The published Q2 EPS range is approximately $1.48–$1.53, while full-year consensus of $5.70 sits near the top of management’s existing $5.56–$5.72 guidance range. (barchart.com)
This is the most important operating metric in the report.
In Q1, Altria estimated that domestic cigarette shipments declined only 4% after inventory adjustments, versus a 5% industry decline. That was a significant improvement from Q2 2025, when Altria’s adjusted shipments fell 10.5% and industry volumes declined approximately 8.5%. Management attributed the recent moderation partly to slower consumer migration into illicit disposable e-vapor products. (investor.altria.com)
Because the year-ago comparison is so favorable, Q2 should show much better reported volume trends even if conditions weakened somewhat from Q1. The market will likely view an adjusted decline in the mid-single digits as broadly constructive. A return toward high-single-digit declines would call into question the Q1 thesis and put more pressure on pricing.
Investors should focus on:
Altria generated 6.3% net price realization in Q1, supporting 6.3% growth in smokeable adjusted operating companies income and a 65.1% adjusted margin. Pricing remains the economic engine of the business.
The risk is continued pressure on lower-income nicotine consumers. In Q1, the industry’s discount share reached 33.3%, up 2.4 percentage points year over year. Marlboro’s total-category share fell to 39.7%, although its share within the premium segment improved to 59.5%. Basic captured much of the discount growth, allowing Altria to retain consumers within its own portfolio. (investor.altria.com)
Q2 also includes the broader rollout of Marlboro Cowboy Cut, positioned as a competitively priced option for price-sensitive Marlboro smokers. The key question is whether this and Basic can protect total company share without causing excessive cannibalization or promotional spending.
Constructive outcome: Marlboro premium share remains around 59.5%, total PM USA share holds or rises, and strong net pricing continues.
Negative outcome: Marlboro’s total share falls faster, promotional investment rises materially, or discount mix offsets too much of the pricing benefit.
Q2 2025 smokeable adjusted operating income was $2.95 billion, with a 64.5% adjusted margin. Q1 2026 margin was already 65.1%, giving Altria a reasonable chance to show year-over-year margin expansion despite higher promotional and manufacturing costs. (investor.altria.com)
Management previously said cigarette export volume and refunds of duties paid on imported cigarettes should increase as 2026 progresses. This could provide an additional profit tailwind, although the company is also spending on contract-manufacturing capacity.
Investors should separate:
Strong segment profit supported mainly by pricing and stable costs would be higher quality than a beat driven primarily by tax or duty timing.
Altria nationally expanded FDA-authorized on! PLUS in late March. At the end of Q1, the product was available in roughly 100,000 stores covering approximately 85% of nicotine-pouch category volume. (investor.altria.com)
Q1 total on! shipments grew 17.6% to 46.2 million cans, but the figure included pipeline inventory for the launch. Q2 will provide the first meaningful evidence of nationwide retail demand.
The comparisons are challenging:
The best indicators will be:
The category itself is growing rapidly, but Altria is losing share within it. Merely reporting higher shipments would not resolve that concern if retail share remains weak.
Altria’s oral segment remains highly profitable, but on! PLUS marketing and unfavorable mix are dilutive to margins. Q1 adjusted operating margin fell 1.8 percentage points to 67.4%, while the Q2 2025 comparison is a relatively demanding 68.7%. (investor.altria.com)
Some margin compression is acceptable if it accompanies improving on! PLUS demand. The less attractive result would be continued margin pressure without stabilization in pouch share.
Management currently expects 2026 adjusted EPS of $5.56–$5.72, representing growth of 2.5%–5.5%. It reaffirmed that range after the Q1 beat, explaining that macroeconomic uncertainty warranted caution, while noting that earnings growth should now be more balanced between the first and second halves. (investor.altria.com)
At the $1.50 quarterly consensus, first-half EPS would be approximately $2.82. That is exactly half of the current guidance midpoint of $5.64. However, full-year consensus of $5.70 implies second-half EPS of roughly $2.88 and sits near the top of management’s range.
That creates three possible outcomes:
Altria narrowed its annual guidance at the Q2 report last year. Given the strong Q1 and current consensus, investors may again expect at least some narrowing. (investor.altria.com)
Altria entered Q2 with $720 million remaining under its $2 billion repurchase program, which expires at year-end. It had repurchased 4.5 million shares during Q1 for $280 million at an average price of $62.33. (investor.altria.com)
Investors should watch:
At the current $1.06 quarterly dividend, the annualized payout is $4.24 per share, or about 74% of the $5.70 full-year consensus estimate.
This will be Sal Mancuso’s first quarterly call as CEO and Heather Newman’s first as CFO following the May 14 leadership transition. Mancuso previously served as CFO and was central to the company’s capital allocation and guidance framework, so a sudden strategic shift is unlikely. Still, investors will listen for changes in emphasis around reinvestment, smoke-free products, the ABI stake and repurchases. (investor.altria.com)
Existing guidance assumes NJOY ACE does not return to the market during 2026. Therefore, a continued absence should not affect guidance. Any concrete legal or commercialization progress would represent optionality rather than an earnings requirement. (investor.altria.com)
The strategic tension is worth monitoring:
The likely earnings debate is less about the headline consensus beat and more about the quality and durability of Altria’s cigarette improvement.
A report showing mid-single-digit cigarette declines, continued premium-segment strength, healthy smokeable margins and initial on! PLUS share stabilization would support the view that Altria can earn near the top of guidance. Conversely, a mechanically strong EPS result driven by duty refunds or pipeline inventory—without better retail trends—would be less convincing.
After a roughly 30% year-to-date rally, a routine beat and reaffirmation may not be enough for further upside. The cleanest positive catalyst would be higher or narrowed guidance backed by sustainable combustible performance and credible on! PLUS sell-through.